Press Releases

Apr 25, 2018

FDA accepts for review Supplemental Biologics License Application for 0.5 mL dose of Fluzone® Quadrivalent (Influenza Vaccine) in children 6-35 months of age

- If approved, health care professionals will be able to use the same 0.5 mL dose of Fluzone Quadrivalent vaccine with all patients ages 6 months and older for whom flu vaccination is recommended - which may provide more flexibility and convenience to immunizers.
Mar 27, 2018

FDA approves Toujeo® Max SoloStar®

* Max SoloStar holds more insulin than any other long-acting insulin pen
- Photos 1
Mar 27, 2018

New survey reveals many misconceptions exist about allergies, illustrating the need for greater education

- Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
- Video 4
- Photos 3
Mar 10, 2018

Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

* Precision medicine approach will focus efforts on high-risk patients, such as those who have had heart attacks or unstable angina and cannot reduce their LDL-C below 100 mg/dL despite maximally-tolerated statins
Mar 10, 2018

Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

* ODYSSEY OUTCOMES trial met its primary endpoint, demonstrating that high-risk patients who added Praluent® (alirocumab) Injection to maximally-tolerated statins experienced significantly fewer major adverse cardiovascular events compared to those on maximally-tolerated statins alone

Show per page

Print
Email page
RSS